Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of RO7247669 ± tiragolumab versus atezolizumab in untreated, platinum-ineligible locally advanced or metastatic urothelial carcinoma
CTR20223212Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tobemstomig in transitional cell carcinoma (TCC), sponsored by Roche. Started Dec 2022; status: completed.
02
Drugs
tobemstomig
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20223212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223212.